Get the Stockscreener App
0.1138
5.25%
-0.0063
Pre-market:
.12
0.0062
+5.45%
Liminatus Pharma Inc stock is traded at $0.1138, with a volume of 1.59M.
It is down -5.25% in the last 24 hours and down -36.78% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
See More
Previous Close:
$0.1201
Open:
$0.12
24h Volume:
1.59M
Relative Volume:
0.19
Market Cap:
$5.11M
Revenue:
-
Net Income/Loss:
$-11.00M
P/E Ratio:
-0.2877
EPS:
-0.3956
Net Cash Flow:
$-11.99M
1W Performance:
-14.05%
1M Performance:
-36.78%
6M Performance:
-85.48%
1Y Performance:
-99.06%
1-Day Range:
$0.1107
$0.125
1-Week Range:
$0.1107
$0.1489
52-Week Range:
$0.1107
$33.66
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
0.1138 | 5.39M | 0 | -11.00M | -11.99M | -0.3956 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Liminatus Pharma Inc Stock (LIMN) Latest News
Liminatus Pharma (LIMN) Faces Selling Pressure, Testing Key Support at $0.11Money Flow - newsline.com
Liminatus Pharma Warrants (LIMNW) Holds at $0.08 as Trading StallsPut Flow Alert - newsline.com
Liminatus Pharma (LIMN) Extends Decline, Testing Key Support at $0.11OBV Breakout - newsline.com
LIMN Should I Buy - Intellectia AI
Liminatus Pharma Warrants (LIMNW) Hold Steady Near Key Support LevelVolume Oscillator - newsline.com
Liminatus Pharma (LIMN) Slips 5.77% as Selling Pressure Persists Below $0.14 ResistanceJelly Roll Trade - newsline.com
Liminatus Pharma Inc. (LIMN) Slides 5.95% as Stock Tests Key Support at $0.13Regression Channel - newsline.com
Liminatus Pharma secures $1.9M cash via warrant exercises - MSN
Liminatus Pharma Secures Liquidity Through Warrant Inducement Deal - TipRanks
[8-K] Liminatus Pharma, Inc. Reports Material Event - Stock Titan
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - The Manila Times
Liminatus Pharma (NASDAQ: LIMN) cuts warrant exercise price; 13.8M warrants tied to 20.7M shares - Stock Titan
Liminatus Pharma (LIMN) Slides 8.89%: Testing Key $0.15 Support LevelVolatility Stop - newsline.com
Liminatus Pharma (LIMN) Slips 6% as Stock Tests Key Support at $0.16Order Block - newsline.com
LIMINATUS PHARMA, INC. Files Form 8-K for NASDAQ Listing – Company Information and SEC Filing Details - Minichart
Liminatus Pharma (LIMN) Holds Steady Near Resistance – Consolidation Phase May Precede Directional MoveSentiment Extreme - newsline.com
Liminatus Pharma Appeals Nasdaq Delisting, Listing Temporarily Intact - TipRanks
Liminatus Pharma Received Notice of Delisting - TradingView
Liminatus Pharma (LIMN) appeals Nasdaq delisting after market value shortfall - Stock Titan
Liminatus Pharma Inc. (LIMN) Surges Over 12% as Bullish Momentum BuildsBPI Reversal - The Legal Advocate
Liminatus Pharma - The Pharma Letter
Liminatus Pharma (LIMN) Shares Slide 3.25% as Selling Pressure Mounts Near SupportRetail Volume - newsline.com
Liminatus Pharma(LIMN) Stock Options Chain | Quotes & News - Moomoo
Liminatus announces proposed merger with InnocsAI - The Pharma Letter
Liminatus Pharma notifies NASDAQ of impending delisting; plans to appeal - MSN
Liminatus Pharma is trending overnight — here's why LIMN stock surged over 79% in after-hours session - MSN
Liminatus Pharma (LIMN) Faces Delisting from Nasdaq - GuruFocus
Liminatus Pharma (LIMN) Faces Nasdaq Delisting Notice Amid Compl - GuruFocus
Liminatus Pharma (LIMN) Plunges 31% as Support Level Approaches – Key Levels to WatchExpert Breakout Alerts - Newser
Liminatus Pharma receives Nasdaq delisting notice - TipRanks
Number of shareholders of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
LIMN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Unusual volume stocks in Friday's session - ChartMill
Liminatus Pharma (LIMN) Stock: Surges Ahead of Nasdaq Delisting Deadline - MEXC
Liminatus Pharma (LIMN) Stock: Nasdaq Delisting Warning Sparks Volatile Trading Session - Blockonomi
Liminatus Pharma (LIMN) Stock Jumps 31% Despite Looming Nasdaq Delisting Threat - MoneyCheck
Liminatus Pharma faces Nasdaq delisting after compliance failure - Investing.com India
Liminatus Pharma faces Nasdaq delisting after compliance failure By Investing.com - Investing.com Australia
Liminatus Pharma to be delisted from Nasdaq for failing market value rules, plans to appeal. - Pluang
Liminatus Pharma Announces Nasdaq Delisting Notification - lincolnjournal.com
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance With Market Value Requirements - Moomoo
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements - Quiver Quantitative
Liminatus Pharma faces Nasdaq delisting after market value shortfall - Stock Titan
Liminatus Pharma Inc Stock (LIMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):